U.S., March 7 -- ClinicalTrials.gov registry received information related to the study (NCT06862739) titled 'Glycemic Control with Triple Pathway Approach Through Empagliflozin, Linagliptin and Metformin Combination' on Feb. 19.
Brief Summary: The efficacy and safety of a triple-pill combination therapy for advanced type 2 diabetes care. The study aims to assess the impact of 3 Oral Anti Diabetic (OAD) drugs on metabolic control, patient compliance, weight management, quality of life, diabetic treatment satisfaction and frequency of hypoglycemic events by combining them into a fixed-dose single pill.
Study Start Date: April, 2025
Study Type: INTERVENTIONAL
Condition:
Diabetes Mellitus
Type 2 DM
Intervention:
COMBINATION_PRODUCT: Empa...